Latest News
AGC Biologics Acquires Commercial Facility to Expand Production Scale
Wednesday 03 June 2020

US-based biopharmaceutical contract development manufacturing organisation AGC Biologics has purchased a Boulder, Colorado commercial manufacturing facility from AstraZeneca, will provide AGC Biologics to increase global capacity and extend manufacturing scale, the company said.

Terms of the transaction were not disclosed.

The Colorado facility is a large-scale biopharmaceutical manufacturing facility that houses two 20,000 liter (total volume) stainless steel mammalian cell bioreactors.

It also has more than 20 acres with multiple opportunities for future expansions, including space for up to four more 20,000 liter bioreactors.

The automated and cost effective facility is very well suited for high volume commercial production and high titer antibody processes.

AGC Biologics employs more than 1000 employees worldwide. AGC Biologics' global network spans three continents, with cGMP-compliant facilities in Seattle, Washington; Copenhagen, Denmark; Heidelberg, Germany; and Chiba, Japan.
Date Published: 03/06/2020